Prognostic Factors Associated with Acute Heart Failure in Patients Admitted for COVID-19: Analysis of the SEMI-COVID-19 Registry

Introduction: Since the beginning of the COVID-19 pandemic in March 2020, an intimate relationship between this disease and cardiovascular diseases has been seen. However, few studies assess the development of heart failure during this infection. This study aims to determine the predisposing factors for the development of heart failure (HF) during hospital admission of COVID-19 patients. Methodology: A retrospective and multicenter study of patients with HF admitted for COVID-19 in 150 Spanish hospitals (SEMI-COVID-19 Registry). A bivariate analysis was performed to relate the different variables evaluated in patients developing heart failure during hospital admission. A multivariate analysis including the most relevant clinical variables obtained in bivariate analyses to predict the outcome of heart failure was performed. Results: A total of 16.474 patients hospitalized for COVID-19 were included (57.5% men, mean age 67 years), 958 of them (5.8%) developed HF during hospitalization. The risk factors for HF development were: age (odds ratio [OR]): 1.042; confidence interval 95% (CI 95%): 1.035–1.050; p < 0.001), atrial fibrillation (OR: 2.022; CI 95%: 1.697–2.410; p < 0.001), BMI > 30 kg/m2 (OR: 1.460 CI 95%: 1.230–1.733; p < 0001), and peripheral vascular disease (OR: 1.564; CI 95%: 1.217–2.201; p < 0.001). Patients who developed HF had a higher rate of mortality (54.1% vs. 19.1%, p < 0.001), intubation rate (OR: 2,36; p < 0.001), and ICU admissions (OR: 2.38; p < 0001). Conclusions: Patients who presented a higher risk of developing HF were older with cardiovascular risk factors. The risk factors for HF development were age, atrial fibrillation, obesity, and peripheral vascular disease. In addition, patients who developed HF more frequently required to be intubated or admitted to the ICU.

[1]  E. Tsai,et al.  Cell-Specific Mechanisms in the Heart of COVID-19 Patients , 2023, Circulation research.

[2]  Qi Liu,et al.  Effect of continuing the use of renin–angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis , 2023, BMC Infectious Diseases.

[3]  Jinkwon Kim,et al.  Association of atrial fibrillation with infectivity and severe complications of COVID‐19: A nationwide cohort study , 2022, Journal of medical virology.

[4]  D. Morrow,et al.  Epidemiology of Acute Heart Failure in Critically Ill Patients With COVID-19: An Analysis From the Critical Care Cardiology Trials Network , 2022, Journal of Cardiac Failure.

[5]  Le Huu Nhat Minh,et al.  COVID-19 and arrhythmia: An overview , 2021, Journal of Cardiology.

[6]  S. Basili,et al.  Prevalence of right ventricular dysfunction and impact on all-cause death in hospitalized patients with COVID-19: a systematic review and meta-analysis , 2021, Scientific Reports.

[7]  R. Gómez-Huelgas,et al.  [Clinical characteristics and risk factors for mortality upon admission in patients with heart failure hospitalized due to COVID-19 in Spain]. , 2021, Revista clinica espanola.

[8]  G. Lip,et al.  Prevalence and Impact of Atrial Fibrillation in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis , 2021, Journal of clinical medicine.

[9]  O. Werz,et al.  SARS-CoV-2 Causes Severe Epithelial Inflammation and Barrier Dysfunction , 2021, Journal of Virology.

[10]  Z. Şi̇mşek,et al.  New onset atrial fibrilation and risk faktors in COVID-19 , 2021, Journal of Electrocardiology.

[11]  T. Hinks,et al.  Azithromycin in viral infections , 2020, Reviews in medical virology.

[12]  A. Borobia,et al.  Heart failure in COVID‐19 patients: prevalence, incidence and prognostic implications , 2020, European journal of heart failure.

[13]  C. Tascini,et al.  Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key? , 2020, Frontiers in Immunology.

[14]  R. Starling,et al.  Heart failure and COVID-19 , 2020, Heart Failure Reviews.

[15]  J. Ramos-Rincón,et al.  Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Registry , 2020, Revista Clínica Española (English Edition).

[16]  Irfan Ahmed Rind,et al.  The impact of COVID‐19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic , 2020, European journal of heart failure.

[17]  S. Solomon,et al.  COVID‐19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease , 2020, European journal of heart failure.

[18]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[19]  Sharukh Lokhandwala,et al.  Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. , 2020, JAMA.

[20]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[21]  Marco Falcone,et al.  Cardiovascular Complications and Short-term Mortality Risk in Community-Acquired Pneumonia , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  Héctor Bueno,et al.  Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica , 2016 .

[23]  P. Seferovic,et al.  Heart Failure in Patients with Diabetes Mellitus. , 2016, Cardiac failure review.

[24]  J. Penninger,et al.  SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS , 2009, European journal of clinical investigation.

[25]  V. Zarubaev,et al.  Clinical Research , 2022 .

[26]  S. Yiu,et al.  Left Ventricular Performance in Patients With Severe Acute Respiratory Syndrome: A 30-Day Echocardiographic Follow-Up Study , 2003, Circulation.

[27]  Douglas W Mahoney,et al.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.

[28]  G. Fonarow,et al.  Epidemiology and risk profile of heart failure , 2011, Nature Reviews Cardiology.